Abstract
The vesicular acetylcholine transporter (VAChT) is a glycoprotein responsible for the accumulation of acetylcholine into pre-synaptic vesicules of cholinergic neurons. Cholinergic innervation has been shown to be decreased at the earlier stages of Alzheimer's disease (AD). Thus, the expression of VAChT has been correlated with the severity of the dementia and has been considered as a significant diagnostic target for AD. To this end numerous radioligands based on the vesamicol scaffold have been developed for imaging the VAChT using positron emission tomography (PET). Among the various radioligands only a small number have been evaluated in vivo in non-human primate and human. Despite promising in vitro, ex vivo and first in vivo studies, most of them are unsuitable for clinical use in humans due to poor selectivity over σ receptors, low extraction from the blood, slow brain kinetics or fast metabolism. To date (-)-[11C]OMV (1), (-)-[11C]MABV (2), (-)-[18F]-FEOBV (6), (-)-trans-2-hydroxy-3-(4-(4-[18F]fluorobenzoyl)piperidine) tetralin (8) and [18F]FBMV (12) are promising radioligands for the VAChT, though further validation is required to confirm their clinical usefulness.
Keywords: VAChT, Alzheimer’s disease, benzovesamicol, positron emission tomography, fluorine-18, carbon-11, PET.
Current Topics in Medicinal Chemistry
Title: PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT)
Volume: 10 Issue: 15
Author(s): Nicolas Giboureau, Ian Mat Som, Aurelie Boucher-Arnold, Denis Guilloteau and Michael Kassiou
Affiliation:
Keywords: VAChT, Alzheimer’s disease, benzovesamicol, positron emission tomography, fluorine-18, carbon-11, PET.
Abstract: The vesicular acetylcholine transporter (VAChT) is a glycoprotein responsible for the accumulation of acetylcholine into pre-synaptic vesicules of cholinergic neurons. Cholinergic innervation has been shown to be decreased at the earlier stages of Alzheimer's disease (AD). Thus, the expression of VAChT has been correlated with the severity of the dementia and has been considered as a significant diagnostic target for AD. To this end numerous radioligands based on the vesamicol scaffold have been developed for imaging the VAChT using positron emission tomography (PET). Among the various radioligands only a small number have been evaluated in vivo in non-human primate and human. Despite promising in vitro, ex vivo and first in vivo studies, most of them are unsuitable for clinical use in humans due to poor selectivity over σ receptors, low extraction from the blood, slow brain kinetics or fast metabolism. To date (-)-[11C]OMV (1), (-)-[11C]MABV (2), (-)-[18F]-FEOBV (6), (-)-trans-2-hydroxy-3-(4-(4-[18F]fluorobenzoyl)piperidine) tetralin (8) and [18F]FBMV (12) are promising radioligands for the VAChT, though further validation is required to confirm their clinical usefulness.
Export Options
About this article
Cite this article as:
Giboureau Nicolas, Mat Som Ian, Boucher-Arnold Aurelie, Guilloteau Denis and Kassiou Michael, PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT), Current Topics in Medicinal Chemistry 2010; 10 (15) . https://dx.doi.org/10.2174/156802610793176846
DOI https://dx.doi.org/10.2174/156802610793176846 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Chemistry and Pharmacology of Genistein
The Natural Products Journal A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates
Current Neuropharmacology Cholesterol, Copper and Aβ in Controls, MCI, AD and the AD Cholesterol- Lowering Treatment Trial (ADCLT)
Current Alzheimer Research The Parietal Atrophy Score on Brain Magnetic Resonance Imaging is a Reliable Visual Scale
Current Alzheimer Research Nanostructured Lipid Carriers (NLCs) for Drug Delivery: Role of Liquid Lipid (Oil)
Current Drug Delivery Targeting Post-Translational Remodeling of Ryanodine Receptor: A New Track for Alzheimer's Disease Therapy?
Current Alzheimer Research Screening for Amyloid Aggregation: In-Silico, In-Vitro and In-Vivo Detection
Current Protein & Peptide Science The Role of HIV-1 DNA as an Additional Marker of HIV-1 Infection
Current HIV Research Acute Management in Very Old Patients: Is Thrombolysis Safe?
Cardiovascular & Hematological Disorders-Drug Targets Amino Thiols, Detoxification and Oxidative Stress in Pre-Eclampsia and Other Disorders of Pregnancy
Current Pharmaceutical Design Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic:Gamma-Secretase Inhibitors and Modulators as a Therapeutic Approach to Alzheimers disease (Guest Editor: Bruno P. Imbimbo)]
Current Topics in Medicinal Chemistry Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological Perspectives
Current Alzheimer Research Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Issues of Quantitative Metabolic Brain Imaging with Small Animal PET in Mice
Current Medical Imaging Amyloid Deposition and Inflammation in APPswe/PS1dE9 Mouse Model of Alzheimers Disease
Current Alzheimer Research Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment
Current Alzheimer Research COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry